Developing differentiated therapies that can improve the health of patients with liver and gastrointestinal (GI) diseases

NASH is expected to become the leading cause for liver transplants in the United States.

Inflammatory bowel disease is increasing in prevalence worldwide

Metacrine is building a pipeline of potential best-in-class FXR agonist therapeuties for NASH and other GI diseases

Our Company

We are a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and GI diseases.

Latest News

November 23, 2020

Metacrine to Participate in Upcoming Investor Conferences

November 12, 2020

Metacrine Reports Business Updates and Third Quarter 2020 Financial Results

Programs

Our most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases.